---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-25-000051"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T19:32:29.301514+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pacira settles EXPAREL patent litigation; Fresenius licensed to sell generic from early 2030

## Summary
- Settlement with Fresenius Kabi, eVenus, Jiangsu Hengrui resolves all patent suits over EXPAREL (bupivacaine liposome).
- Fresenius gets license to sell volume-limited generic starting on confidential date in early 2030, before last patent expiry in 2044.
- Volume-limited percentages start at high-single-digit, increase to low-thirties in 2033, capped at high-thirties for final three years.
- Unlimited generic license granted no earlier than 2039.
- Pacira pays Fresenius $7 million for expected litigation cost savings.

## SEC filing metadata
- accession: 0001396814-25-000051
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000051/0001396814-25-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000051/pcrx-20250407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-25-000051
- JSON: https://secwatch.observer/filing/0001396814-25-000051.json
- Plain text: https://secwatch.observer/filing/0001396814-25-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.